Russia's Enteromix Cancer Vaccine Shows 100% Efficacy in Trials

Early trial success doesn't guarantee long-term effectiveness, and the small sample size of 48 volunteers raises questions about broader applicability. Significant logistical challenges around personalized vaccine production, cold-chain storage and genomic profiling must be addressed before this becomes viable.